Tags

Type your tag names separated by a space and hit enter

Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Leuk Lymphoma. 2014 Feb; 55(2):263-9.LL

Abstract

Recent clinical data suggest remarkable activity of ibrutinib, the first-in-class covalent inhibitor of Bruton's tyrosine kinase (BTK), in chronic lymphocytic leukemia (CLL), as well as excellent activity in other B cell malignancies, including in particular mantle cell lymphoma and Waldenstrom macroglobulinemia. This review evaluates the data from ongoing clinical and correlative studies of ibrutinib in B cell malignancies with a particular focus on CLL, and considers these data in the context of other B cell receptor pathway inhibitors.

Authors+Show Affiliations

Director, CLL Center, Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA , USA , and Department of Medicine, Harvard Medical School , Boston, MA , USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

23656200

Citation

Brown, Jennifer R.. "Ibrutinib in Chronic Lymphocytic Leukemia and B Cell Malignancies." Leukemia & Lymphoma, vol. 55, no. 2, 2014, pp. 263-9.
Brown JR. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. Leuk Lymphoma. 2014;55(2):263-9.
Brown, J. R. (2014). Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. Leukemia & Lymphoma, 55(2), 263-9. https://doi.org/10.3109/10428194.2013.803226
Brown JR. Ibrutinib in Chronic Lymphocytic Leukemia and B Cell Malignancies. Leuk Lymphoma. 2014;55(2):263-9. PubMed PMID: 23656200.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. A1 - Brown,Jennifer R, Y1 - 2013/06/24/ PY - 2013/5/10/entrez PY - 2013/5/10/pubmed PY - 2014/10/7/medline SP - 263 EP - 9 JF - Leukemia & lymphoma JO - Leuk. Lymphoma VL - 55 IS - 2 N2 - Recent clinical data suggest remarkable activity of ibrutinib, the first-in-class covalent inhibitor of Bruton's tyrosine kinase (BTK), in chronic lymphocytic leukemia (CLL), as well as excellent activity in other B cell malignancies, including in particular mantle cell lymphoma and Waldenstrom macroglobulinemia. This review evaluates the data from ongoing clinical and correlative studies of ibrutinib in B cell malignancies with a particular focus on CLL, and considers these data in the context of other B cell receptor pathway inhibitors. SN - 1029-2403 UR - https://www.unboundmedicine.com/medline/citation/23656200/Ibrutinib_in_chronic_lymphocytic_leukemia_and_B_cell_malignancies_ L2 - http://www.tandfonline.com/doi/full/10.3109/10428194.2013.803226 DB - PRIME DP - Unbound Medicine ER -